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Abstract
Background: Parkinson’s disease (PD) patients may experience ‘sleep benefit’ (SB): a temporarily improved mobility
upon awakening. SB has mainly been studied retrospectively using questionnaires, but it remains unclear whether it
is associated with actual changes in motor functioning.
Methods: We performed a prospective study on sleep-related changes in motor functioning, using a PD symptom
diary during 7 days in 240 randomly selected PD patients (140 men; 66.8 ± 9.6 years; disease duration 9.3 ± 6.2 years).
Afterwards, patients received a questionnaire on the possible subjective experience of SB.
Results: Using the PD symptom diary, a positive change in motor function was observed after 267 nights (17.8%)
and after 138 daytime naps (23.4%). Based on these results, 75 patients (32%) were classified as having SB. In response
to the subsequent questionnaire, 73 patients (31%) reported SB. Interestingly, the groups with SB according to either
the diary or the questionnaire overlapped only partially: outcomes were congruent in 63% of subjects (both negative
49%, both positive 14%). In both the diary and questionnaire, patients with SB showed a longer disease duration and
longer medication use. According to the questionnaire, there was a trend towards a shorter sleep duration and lower
sleep efficiency in the SB group. The mean change in motor function after sleep as assessed using the diary was higher
in patients reporting subjective SB.
Conclusion: We show that the subjective experience of SB in PD is not always related to an actual increase in reported
motor function after sleep. Defining SB using either a symptom diary or a questionnaire on subjective experience,
results in only partly overlapping groups. These data suggest that SB may be a more heterogeneous phenomenon
than previously thought and that subjective experience of symptom severity is not necessarily related to actual
motor function.
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Background
Sleep in Parkinson’s disease (PD) is generally associated
with sleep disorders, which affect 60-98% of PD patients
[1-3]. However, clinicians have repeatedly noted reports
of patients experiencing a Parkinson-specific beneficial
effect of sleep. Contrary to what would be expected after a
night without medication, some patients describe a tempor-
arily improved mobility upon awakening. In the early eight-
ies, Marsden was the first to describe this phenomenon,
coining the term “sleep benefit” (SB) [4]. Subjective patient
reports suggest that the effect of SB may be rather pro-
nounced, with patients sometimes comparing SB to the
“on” state as induced by dopaminergic medication. Some
PD patients can even delay or skip their morning dose of
medication because of SB [5]. Although typically described
after nocturnal sleep, SB may also occur after daytime
naps [5-8]. In this study, we assess SB using a recently
suggested, explicit definition: SB is the experience of a tem-
porary decrease in PD symptoms upon awakening after a
period of sleep (night or daytime), before drug intake; the
patient is feeling as good as “on” (or better) [9].
In most studies, questionnaires have been used to evalu-
ate the prevalence and characteristics of SB. Results showed
a rather consistent prevalence estimate, ranging from 33
to 55% of PD patients who recognized the phenomenon
[9]. However, it remains unknown why some PD patients
experience SB while others do not. Possible determinants
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of SB were assessed by several research groups, including
age, age at onset, disease duration and presence of motor
fluctuations [5,6,8,10-12]. Results varied widely and no
consistent SB-associated variables have been found to
date. One explanation for this may be the prominent dif-
ferences in the definition of SB that were applied in the
various studies [9]. Furthermore, patients often have diffi-
culties giving an accurate account of their general motor
functioning after sleep [13].
Here we performed a prospective study in a large group
of PD patients using tailored symptom diaries. In the
diary, patients provided an indication of specific motor
functioning before and directly after every period of sleep.
Using this approach, we obtained sleep-related changes in
subjective motor functioning over multiple days, without
explicitly asking patients about the phenomenon of SB.
The objective of this study was to gain more insight into
the nature of SB and the magnitude of its effect.
Methods
Subjects
Information letters about the study were sent to 475 PD
patients under treatment at the Parkinson Centre Nijmegen
and the associated national ParkinsonNet. Subsequently,
these patients were contacted by telephone to provide
general study information and - when interested - to book
an appointment for completing the SB-diary. After tele-
phone consultation, 292 patients agreed to participate, of
which 240 patients completed both the diary and ques-
tionnaire. The study was approved by the Medical Ethical
Committee of the Radboud university medical centre. All
patients provided written informed consent to participate.
Diary
The symptom diary was based on the SCOPA Diary
Card (SCOPA DC) [14], a validated instrument to assess
changes in motor functioning during the day. Before and
directly after every night of sleep and every daytime nap,
patients answered four questions with respect to PD-
related motor functioning. The diary was completed at
bedtime and directly at awakening, before medication
intake. Patients indicated on a four-point scale how well
they could perform three activities, i.e. walking, changing
position and using their hands. These activities have
proven to give a reliable indication of general motor func-
tioning [14]. In addition, the question on sleep quality from
the SCOPA DC was used and we added an extra question
on feeling rested upon awakening, all recorded using four-
point Likert scales.
Medication taken within 2 hours before a period of sleep
or during the night-time was recorded in the diary. All
dopaminergic medication was converted into the L-dopa
equivalent dose (LED), using the formula described by
Tomlinson et al. [15].
Patients completed the symptom diary during one week,
before and directly after every period of sleep (both night
sleep and daytime naps). Importantly, in this phase of
the study, patients were not explicitly informed about
the phenomenon of SB.
Questionnaire
After completing the diary week, patients received an
extensive questionnaire, in which demographic charac-
teristics and clinical information were obtained. The
Pittsburgh Sleep Quality Index (PSQI) provided a vali-
dated measure of nocturnal sleep quality during the past
month [16], therefore the questionnaire had to be com-
pleted within a month after the symptom diary.
Subsequently, a brief explanation of SB was given in
the questionnaire. This explanation of SB was based on
the revised definition of SB recently presented by our
group [9]. Afterwards, patients were asked whether they
were familiar with SB, and if yes, how often they experi-
enced SB. Finally, information was obtained on the dur-
ation, degree of improvement and variability of the SB
experience (see Additional file 1 for the translated SB
questionnaire).
Analyses
For all analyses, night sleep and daytime naps were
regarded separately. Motor functioning was defined as
the sum of the three functioning questions in the diary
(i.e. walking, changing position, using hands). Changes
in motor function in relation to sleep were calculated by
subtracting post-sleep motor scores from pre-sleep motor
functioning. This was done for every period of sleep
separately.
A night with a positive change (better functioning in the
morning than in the evening) was regarded as a “SB-night”.
The same approach was used for daytime naps. Patients
were classified as having SB, when SB was present after at
least 2 nights or 2 naps during the 7 day period.
All analyses were performed in SPSS for Windows ver-
sion 20. Groups with and without SB were compared using
t-tests or chi2-tests. Correlations were analyzed using
Spearman’s correlations. Alpha was set to 0.01 to correct
for multiple comparisons.
Results
Of the 292 participating patients, a total of 240 completed
the 7-day motor diary and the subsequent SB question-
naire. Mean age was 66.8 ± 9.6 years (range 33–94 years)
and the number of men was 140 (58.3%). Mean disease
duration was 9.3 ± 6.2 years (range 1–35 years), with a
mean age of PD onset of 57.4 ± 12.2 years (range 22–87
years). The most important reasons for dropout were:
illness (25), patients considering the symptom diary too
confronting and/or demanding (16) and being lost to
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follow up (9). Patients dropping out were older than those
who finished the diary (72.3 ± 10.6 vs. 66.8 ± 9.6 years,
p < 0.001) but there were no gender differences between
the groups.
SB diary
In 5 diaries more than 50% of the questions were missing;
these diaries were excluded from the analyses. Valid infor-
mation was obtained from a total of 1496 nights (91%)
and 591 (90%) naps (mean duration 21.7 ± 45.9 min). A
positive change in motor function was observed after 267
nights (17.8%), and after 138 naps (23.4%). Based on these
results, 76 patients (32%) were classified as having SB, 44
patients (58%) only showed sleep benefit after night sleep,
11 (14%) only after an afternoon nap and 21 patients
(28%) after both. None of the patients had SB after every
night of the week. In Table 1, the number of patients are
listed with the number of nights associated with a positive
change in motor function, over the measurement week.
When comparing patients with and without SB based on
the symptom diary, we found that patients with SB had
used PD medication during a longer period of time and
showed a trend towards longer disease duration (Table 2).
There were no differences in gender distribution, age, or
sleep quality between patients with and without SB.
In the SB group, 22 patients (28.9%) used long-acting
L-dopa and 5 patients (6.6%) used dopamine agonists in
the 2 hours before bedtime. In the no-SB group, 30 pa-
tients (19.1%) used long-acting L-dopa and 13 patients
(8.3%) used dopamine agonists in the 2 hours before
bedtime. Benzodiazepines were sometimes used by 9 SB
patients (12%) and 18 no-SB patients (11.5%) and other
sleep modulating drugs were used by 11 patients with
SB (14.7%) and 18 patient without SB (11.5%). For none
of these drugs there was a significant between-group
difference.
When looking at individual nights, we found no signifi-
cant correlations between the amount of overnight change
in motor functioning and self-rated sleep time, sleep
quality or the feeling of being rested upon awakening.
In addition, we found no influence of the amount of
dopaminergic medication taken before and/or during
the night on the occurrence of SB. For the daytime naps,
no association was found between the amount of func-
tioning change after sleep and sleep time, sleep quality,
restorative feeling or dopaminergic medication taken
within 2 hours before the nap.
SB questionnaire
In the questionnaire, 74 patients (31%) indicated to ex-
perience SB. When patients were categorized based on
their own subjective judgment on the presence of SB in
the questionnaire, we found that the SB group not only
had a longer disease duration and a longer history of
medication use, but also a higher daily L-dopa equivalent
dose (Table 1). In addition, patients reporting SB were
younger, and had an earlier age of onset of PD. There
were no differences in overall subjective sleep quality as
assessed by the PSQI between the SB and no-SB group,
although there was a trend towards a shorter sleep dur-
ation as well as a lower sleep efficiency in patients report-
ing SB (Table 1).
Additional information on the characteristics of subject-
ive SB were obtained in the questionnaire as well. Of the
patients recognizing SB, the majority reported to regularly
experience SB after sleep. Strikingly, 28% of patients even
reported that they always experienced SB. The mean esti-
mated duration of SB was 1:03 ± 0:53 hours. At awaken-
ing, 47.1% reported to feel “as good as on medication” and
22.9% reported to feel even better. The remaining 30% of
patients experienced an improvement in functioning, but
perceived it not as good as when on medication. About a
third of the subjects (31.5%) indicated to experience SB
during the night, for example when going to the toilet.
Many patients had the feeling that sleeping longer (47.3%)
or shorter (58.1%) had an influence on the occurrence
of SB.
We also asked patients experiencing SB to give their
own written description of how they feel at waking up.
Some patients gave very characteristic and specific de-
scriptions fitting with SB. However, there were also pa-
tients who rated themselves as having SB, who provided
a much more general description of feeling improved at
awakening, which would fit more with a-specific refresh-
ing effects of sleep (see “Patients description of feeling at
awakening when experiencing sleep benefit”).
Patients description of feeling at awakening when
experiencing sleep benefit
Descriptions characteristic for SB
– “At awakening I feel less rigid, I feel I could skip my
medication if I want to”
Table 1 Patient report of total number of nights per
week with SB according to the PD symptom diary
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– “After a nap I move faster, more flexible and more
natural”
– “After sleeping I feel like I don’t have PD, even my
handwriting is as good as it used to be”
– “Sometimes I forget to take my morning medication,
because I feel so good”
– “For me sleep is the best drug against PD”
– “After a nap it feels like my body is reset”
– “At awakening in the morning I can go to the toilet
by myself, whereas during the rest of the day I need
help with everything”
Descriptions non-characteristic for SB (i.e. general a-specific
sleep effects)
– “I feel very rested, however, I’m still very rigid”
– “I feel less tired after an afternoon nap”
– “In the morning I have more energy than in the
afternoon”
– “After sleeping I feel more relaxed”
Comparing SB diary and questionnaire outcomes
Interestingly, the group of patients classified as having
SB based on the symptom diary, overlapped only par-
tially with the group of patients self-reporting to have
SB in the questionnaire (Table 3). Outcomes of the diary
and the questionnaire were congruent in only 63% of
the subjects (both negative 49%, both positive 14%). A
relevant portion of patients (18%) reported to have SB,
but did not show improvement on the diary. A compar-
able 19% of subjects did show motor improvement after
sleep in the diary, but did not perceive themselves as
having SB.
As the groups with SB according to either the diary or
the questionnaire were not fully overlapping, we com-
bined the outcomes of both instruments in an additional
analysis, which indicated that both instruments may
probe different aspects of SB. Patients with and without
diary-determined SB, did not report differences in the
characteristics and experience of their perceived SB in
the questionnaire.
Moreover, unusual, ‘non-characteristic’ SB descriptions
(e.g. “I feel less tired” or “I have more energy”) could be
provided by patients both with and without SB according
to the diary. Conversely, some patients with very clear,
characteristic and convincing descriptions of SB in the
questionnaire, did not show any improvement in sub-
jective motor function related to sleep in the prospect-
ive diary.
Motor function changes after a daytime nap were larger
in patients subjectively reporting SB in the questionnaire,
compared to those not reporting SB (mean improvement
0.53 ± 1.54 vs. 0.06 ± 0.78 respectively, p < 0.001). A trend
was found in the similar direction when looking at over-
night changes in motor function (mean improvement in
patients with subjective SB 0.01 ± 1.53 vs. -0.12 ± 1.06 in
patients without, p = 0.052).
Discussion
The existence of SB in PD has been reported repeatedly
in the literature [1,4-6,8,10-13]. Here, we examined subject-
ive SB in a structured, prospective design using a 7-day
diary. Additionally, we compared the diary responses to a
more traditional way of assessing SB using a questionnaire.
Table 2 Characteristics of patients with and without SB
SB based on diary SB based on questionnaire
SB no-SB p SB no-SB p
SB 76 (32%) 159 (68%) 74 (31%) 163 (69%)
Men 43 (57%) 94 (59%) 0.741 37 (50%) 102 (63%) 0.068
Age (yrs) 67.3 ± 9.7 66.3 ± 9.6 0.454 63.6 ± 8.2 68.5 ± 9.7 0.000*
Age PD onset (yrs) 56.6 ± 13.6 57.5 ± 11.5 0.587 51.9 ± 11.1 60.0 ± 11.9 0.000*
Duration of PD symptoms (yrs) 10.8 ± 7.0 8.7 ± 5.8 0.019 11.7 ± 6.7 8.2 ± 5.7 0.000*
Duration medication use (yrs) 9.0 ± 6.0 6.8 ± 5.5 0.009* 9.4 ± 6.3 6.5 ± 5.3 0.001*
Daily LED (mg) 752 ± 608 624 ± 409 0.080 804 ± 614 584 ± 382 0.002*
PSQI 7.5 ± 3.9 7.2 ± 3.9 0.680 7.8 ± 4.1 7.0 ± 3.8 0.178
Sleep duration (hrs - PSQI) 6.7 ± 1.3 6.7 ± 1.6 0.960 6.4 ± 1.3 6.8 ± 1.5 0.039
Sleep efficiency (% - PSQI) 78.7 ± 16.1 78.2 ± 17.7 0.840 74.9 ± 14.7 80.3 ± 17.9 0.027
Diary – 5 missing, Questionnaire – 3 missing, *significant difference at α = 0.01.
Table 3 Number of patients with sleep benefit based on
diary or questionnaire
SB based on diary Total
no-SB SB
SB based on questionnaire no-SB 115 (72.3%) 44 (27.7%) 159
SB 41 (56.2%) 32 (43.8%) 73
Total 156 76 232
Percentage shown: within SB based on questionnaire.
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As such, the present study represents the first prospective
assessment of sleep benefit over a longer period of time.
Using either instrument, we found a prevalence of subject-
ive SB of just over 30% and the SB group had longer medi-
cation use and a tendency towards shorter night sleep.
Remarkably, the groups with SB according to the diary and
according to the self-report questionnaire were overlapping
only partially. Many patients showed incongruent results
on the diary and the questionnaire; they either showed im-
provement in the diary, but did not report to experience
this improvement in the questionnaire, or they reported to
experience an improvement after sleeping in the question-
naire that was not present in the diary. Nevertheless, the
mean change in motor function after sleep tended to be
higher in patients reporting subjective SB.
We applied a new approach in studying SB, using a
diary in which structured questions about motor function-
ing reflected the subjective PD motor symptom severity at
that moment. The diary enabled us to prospectively study
patients for more than one night. Furthermore, patients
did not have to indicate their general morning function,
but assessed their functioning at a specific moment on
specific motor domains. This was the first study that ad-
dressed over-night functioning change over a longer
period of time. We chose to do this, to see whether there
was any day-to-day variation in sleep-related symptom se-
verity changes in PD. In previous research, SB has been
treated as an “all or nothing” phenomenon, classifying pa-
tients as having either SB or not at all. Here we show that
this is not necessarily the case. From both the diary and
the questionnaire it became clear that in the majority of
patients, SB was not experienced after every period of
sleep. Although 29% of SB patients (according to the ques-
tionnaire) claimed that their SB was ‘always’ present, none
of the patients had a positive change in functioning in all
of the diary nights.
Our questionnaire provided a carefully formulated def-
inition of SB to make it as clear as possible for the pa-
tients what we were looking for. However, the written
description of their experiences indicated that some pa-
tients may still have misinterpreted the given definition.
Although it was stated that SB is a specific reduction in
PD symptoms, some patients confused it with more gen-
eral and a-specific refreshing effects of sleep, which are
not necessarily related to PD. We previously established
this problem and attributed this to the ill-defined descrip-
tion of SB in earlier studies [9]. We feel that our strict def-
inition increased the specificity to detect SB, which also
fits with the SB prevalence of 31% in our cohort, which is
slightly lower than in previous reports.
In our explanation of SB in the questionnaire, it was
stated that the decrease in PD symptoms should be as
good as feeling “on” (or better). However, 30% of the pa-
tients who reported SB in the questionnaire, subsequently
stated that a symptom decrease was present after sleep,
but not as large as when under the effect of medication.
This may have caused an overestimation of SB prevalence.
On the other hand, among the patients that answered
negatively to the SB question, there were probably also pa-
tients who do experience some improvement after sleep,
although not as large as on medication. Our data certainly
indicate that there is large variation in the degree of symp-
tom change by SB. Here -as well as in previous studies-
some of the patients may have (partly) misinterpreted the
SB definition, incorrectly stating to experience SB. Never-
theless, the characteristic written descriptions given by
some patients, indicate that there may indeed be a group
of PD patients that genuinely benefits from sleep.
Even patients with a highly characteristic and convin-
cing description of perceived SB, did not always show
sleep related symptoms changes in the diary. Therefore,
the incongruence between the results from the diary and
the questionnaire may further imply that these instru-
ments assess different aspects of SB. When discussing SB,
it seems necessary to make a distinction between 1) a sub-
jective general feeling of improvement after sleep and 2) a
specific improvement in actual motor functioning. Both
aspects may contribute to the experiences which patients
perceive as SB. The latter aspect was mostly assessed by
the symptom diary, as we specifically targeted this instru-
ment towards changes in motor function. The definition
of SB in the questionnaire could be interpreted in a more
general way, including non-motor symptoms of PD and/
or a-specific refreshing effects of sleep. Both aspects could
for sure be clinically relevant, but the underlying mecha-
nisms are possibly different. Therefore, this distinction
should be an important point of focus in future research.
We have assessed possible determinants of SB in our
cohort. In both the diary- and questionnaire-determined
SB we found that patients with SB had longer disease
duration and longer medication use. Using the question-
naire we also found that patients with SB were younger,
had a lower age of onset and used higher doses of dopa-
minergics. Similar results have previously been found for
disease duration [5,10,11], medication use [6,11], age of
onset [10,11] and LED [10,11]. Only one other study has
reported a difference in age between SB and non-SB pa-
tients, but found SB patients to be older [5].
In the diary data we found a negative correlation with
the magnitude of SB and self-reported sleep duration
and quality. In addition, in the questionnaire a trend to-
wards shorter sleep duration and lower sleep efficiency
was present in the SB group. This possible association
with shorter and/or worse nighttime sleep with the
presence of SB is in line with a recent polysomnography
study in which a shorter total sleep time and a longer
sleep latency were found in patients experiencing SB
[17]. Together, these data may suggest that SB is in fact
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not related to sleep, or even that sleep deprivation facili-
tates SB. This hypothesis has been put forward in the lit-
erature before [5,13]. When a causal relation between
(good) sleep and improved motor function is abandoned,
the thinking about the putative mechanism underlying SB
may also have to change. The currently most common hy-
pothesis states that dopamine storage in nigral neuronal
terminals are replenished during sleep as the mediator of
SB [9]. However, this would not fit with the association
between poorer sleep quality and SB, although it should
be noted that these results are all based on the evaluation
of nocturnal sleep. SB is also reported after daytime naps
[5-8]; and assessing nap related SB may shed further light
on possible underlying mechanisms. Our study however,
is unsuitable for making strong inferences on these mech-
anistic aspects.
This study had some limitations. In the diary we could
only record planned naps, as it was essential that the pa-
tient completed the diary both before and after a sleep
episode. We probably missed some unplanned and un-
noticed sleep episodes [18]. However, as our classification
of patients having SB relied on an minimum number of
naps with a positive change, this could at worst have led
to an underestimation of patients with SB based on day-
time naps. Furthermore, self-reports of sleep quality are
not always reliable and subjective to various factors in-
cluding affective disorders [19]. However, previous studies
on sleep benefit that included assessment of depressive
symptoms did not find differences between patients with
and without sleep benefit [8,17].
As patients dropping out of the study were older and
may have been different with respect to disease duration
or severity, one should be careful to generalize our find-
ings to the whole PD population.
We used a minimum of 2 nights or naps with any
symptom improvement as a cut-off for SB. Because this
was the first time that SB was studied using a symptom
diary, we had to choose cut-off values. For this particular
study, we chose to be relatively sensitive and to classify
any amount of ‘over-sleep improvement’ that occurred
for more than one day as indicative of SB. Although ar-
bitrary, this is at least a very clear way of defining SB,
allowing comparisons between studies.
Conclusions
We showed that the subjective experience of SB in PD is
not always related to an actual increase in reported motor
function after sleep. Defining SB using either a symptom
diary or a questionnaire on subjective experience, probed
different aspects of the phenomenon, resulting in only
partly overlapping groups. These data suggest that SB may
be a more heterogeneous phenomenon than previously
thought and that subjective experiences of symptom
severity is not necessarily related to actual motor function.
Given its potential clinical relevance as therapeutic inter-
vention, there is now a crucial need for detailed prospective
studies using quantitative objective measures of motor
performance, in relation to objective assessment of sleep
quality. Such studies should also monitor the effects of SB
on non-motor symptoms of PD, including cognitive
deficits and fatigue, as these may potentially improve
in relation to sleep as well.
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